Pharmacodynamics of insulin detemir and insulin glargine assessed by an isoglycemic clamp method in healthy cats

Journal of Veterinary Internal Medicine

Volumn 24, Issue 4, 2010, Pages 870-874

  Gilor, C ^a   Ridge, T K ^a   Attermeier, K J ^a   Graves, T K ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Diabetes mellitus; Feline; Pharmacology

Indexed keywords

ANIMALIA; FELIDAE;

ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; INSULIN; INSULIN DETEMIR;

ANIMAL; ANIMAL DISEASE; ARTICLE; CAT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; GLUCOSE CLAMP TECHNIQUE; MALE; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; CATS; CROSS-OVER STUDIES; FEMALE; GLUCOSE CLAMP TECHNIQUE; HYPOGLYCEMIC AGENTS; INSULIN; MALE;

EID: 77956626114     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2010.0544.x     Document Type: Article

References (16)

1. Marshall RD, Rand JS, Morton JM. Glargine and protamine zinc insulin have a longer duration of action and result in lower mean daily glucose concentrations than lente insulin in healthy cats. J Vet Pharmacol Ther 2008;31:205-212.
2. Nelson RW. Diabetes mellitus. In: Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine - Diseases of the Dog and Cat, 6th ed. Philadelphia, PA: WB Saunders Co; 2005:1575-1579.
3. Fakhoury W, Lockhart I, Kotchie RW, et al. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes. Pharmacology 2008;82:156-163.
4. Danne T, Datz N, Endahl L, et al. Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: Results from a randomized, double-blind, controlled trial. Pediatr Diabetes 2008;9:554-560.
5. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: A metaanalysis. Diabetes Res Clin Pract 2008;81:184-189.
6. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007;9:648-659.
7. Soran H, Younis N. Insulin detemir: A new basal insulin analogue. Diabetes Obes Metab 2006;8:26-30.
8. Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004;21:1498-1504.
9. Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab 2007;9:209-217.
10. Heinemann L, Anderson JH Jr. Measurement of insulin absorption and insulin action. Diabetes Technol Ther 2004;6:698-718.
11. Marshall RD, Rand JS, Morton JM. Insulin glargine has a long duration of effect following administration either once daily or twice daily in divided doses in healthy cats. J Feline Med Surg 2008;10:488-494.
12. Klein O, Lynge J, Endahl L, et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): Comparable timeaction profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007;9:290-299.
13. Swinnen SG, Holleman F, DeVries JH. The interpretation of glucose clamp studies of long-acting insulin analogues: From physiology to marketing and back. Diabetologia 2008;51:1790-1795.
14. Ipp E, Sinai Y, Bar-Oz B, et al. Somatostatin impairs clearance of exogenous insulin in humans. Diabetes 1987;36:673-677.
15. Heinemann L, Linkeschova R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-649.
16. Weaver KE, Rozanski EA, Mahony OM, et al. Use of glargine and lente insulins in cats with diabetes mellitus. J Vet Intern Med 2006;20:234-238.